PITTSBURGH, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the TD Cowen 46th Annual Health Care Conference on March 3, 2026, in Boston. Company executives will take part in a fireside chat scheduled at 3:10 pm ET and host investor meetings throughout the day.
A webcast of the presentation will be available here beginning at 3:10 pm ET on Tuesday, March 3, 2026 and will be posted on the Investors section of the Company’s website.
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK®, the Company’s first commercial product, is the first-ever redosable gene therapy and the first genetic medicine approved in the United States, Europe, and Japan for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).
CONTACT
Investors and Media:
Stéphane Paquette, PhD
Krystal Biotech
spaquette@krystalbio.com

| Nov-10 | |
| Nov-02 | |
| Nov-02 | |
| Nov-02 | |
| Oct-26 | |
| Oct-22 | |
| Oct-15 | |
| Oct-15 | |
| Oct-06 | |
| Sep-03 | |
| Aug-07 | |
| Aug-04 | |
| Aug-03 | |
| Aug-03 |
Read Between These Lines As Eli Lilly, Hot IPO And More Face Key Test
KRYS -8.37%
Investor's Business Daily
|
| Aug-03 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, alerts, and much more.
Learn more about Finviz Elite